Patent Grant
10696709
This invention relates to novel phosphotriazole mRNA 5′-end cap analogs, a composition comprising the same, an RNA molecule incorporating the same, uses thereof and a method of synthesizing, in vitro or in vivo, the RNA molecule, as well as a method of synthesizing a protein or peptide in vitro, or in vivo or in cultured cells, said method comprising translating the RNA molecule.
The 7-methylguanosine (m7G) cap present at the 5′ end of eukaryotic mRNAs plays a crucial role in numerous fundamental cellular processes, mainly by protecting mRNA from premature cleavage and serving as a molecular platform for proteins acting in mRNA transport and translation.1 Thus, chemical modifications of the 5′ cap pave the way to design of molecular tools for selective modulation of cap-dependent processes and, consequently, mRNA metabolism.2 The presence of the 5′ cap is necessary for mRNA surveillance and efficient translation under normal conditions. Chemically synthesized mRNA cap analogs of m7GpppG type are utilized as reagents for in vitro synthesis of capped mRNAs.3
In vitro transcribed (IVT) 5′-capped mRNAs are useful tools for studying mRNA translation, transport, and turnover, and are an emerging class of highly promising therapeutic molecules. IVT mRNAs find application in protein expression in eukaryotic cell, extracts, cultured cells, or even whole organisms. Finally, IVT mRNAs have recently gained great attention as a tool for safe exogenous protein delivery for the purpose of anti-cancer vaccinations and gene-replacement therapies.4
The synthesis of 5′-capped mRNAs by using mRNA cap analogs can be achieved by in vitro transcription.3 By this method, called co-transcriptional capping, the synthesis of RNA is performed by RNA polymerase on DNA template in the presence of all 4 NTPs and a cap dinucleotide, such as m7GpppG. The DNA template is designed to incorporate G as the first transcribed nucleotide. The polymerase initiates the transcription from GTP or m7GpppG, thereby incorporating one of the nucleotides at the 5′ end of the nascent RNA. To increase the percentage of cap analogue incorporation (capping efficiency), the GTP concentration is decreased relative to the other NTPs, and the concentration of the cap dinucleotide is elevated (from 4- to 10-fold excess relative to GTP). Unfortunately, reverse incorporation of cap dinucleotides can potentially occur, resulting in a fraction of ‘Gpppm7G-capped’ RNAs, which are translationally inactive. This problem has been solved by the discovery of ‘anti-reverse cap analogs’ (ARCAs) that are modified at the 2′- or 3′-positions of 7-methylguanosine (usually by replacing one of OH groups by OCH3) to block reverse incorporation5, 6
It has been shown that co-transcriptional capping method enables incorporation at the RNA 5′ end of various modified cap structures. These modified cap structures may carry molecular labels or confer new properties to mRNA such as increased translation efficiency and stability. Especially beneficial cap analogs are among those modified in the triphosphate bridge.7 It has been shown that even single atom substitutions in the 5′,5′-triphosphate bridge can affect the properties of mRNAs significantly. For example, a single atom substitution at the β-position of the oligophosphate bridge of the cap, introduced by the so-called β-S-ARCA, led to significant increase in translation efficiency of mRNA in vitro and in vivo,8, 9 whereas a single O to CH2 substitution at the α-β position led to decrease in translation efficiency.10 The dramatically different biological effects of different single-atom substitutions within the cap indicates on high sensitivity of the translational machinery to oligophosphate chain modification and suggests this is a field for further exploration.
However, the development of novel cap analogues, either as research tools or compounds with medicinal potential, is limited by difficulties associated with the chemical synthesis of these compounds. The synthesis and purification of mono- and dinucleotide cap analogues are challenging due to their highly ionic nature and chemical lability of 7-methylguanosine.11, 12 The usual synthetic approach, based on phosphorimidazolide chemistry and divalent-cation-excess-mediated pyrophosphate bond formation in organic solvent,7, 13, 14 is both time-consuming and labour-intensive, challenging in upscaling, requires multiple purification steps, and occasionally results in complex mixtures of products and side-products that are difficult to separate. Occasionally, as in the case of β-S-ARCA,15 this approach requires also generation of unstable mononucleotide intermediates, which are prone to spontaneous degradation upon storage. Hence, the typical synthetic approach is usually effective for production of cap analogs at low milligram scale, but is rather low throughput and very difficult scale-up. The ability to produce cap analogs in high purity and yield by an easily-scalable synthetic method would be critical for many applications, including in vivo and medicinal applications that require delivery of in vitro synthesized capped mRNAs into animals or humans.
“Click chemistry” is a term that describes a group of chemical reactions that are efficient, have a wide scope, are simple to perform and easy to scale-up, create products in a regio- and stereospecific manner with almost no side-products, and can be carried out in benign solvents such as water. Copper catalyzed azide-alkyne cycloaddition leading to formation of substituted 1,2,3-triazoles is a prime example of such reaction. CuAAC has been widely applied in functionalization of RNA and RNA components,16, 17 including 5′ end labeling,18-22 bioconjugation,23-26 and chemical ligation.27 It has been found that the triazole moiety can replace one or more 5′,3′-phosphodiester bonds in DNA28, 29 and RNA36-33 to generate functional mimics. Piecyk et al.34 reported functionalization of mononucleotide cap analogs by CuAAC click chemistry to obtain analogs containing 1,2,3-triazole moiety at the N2-position of nucleobase, whereas Walczak et al.45 reported cap analogs containing a 1,2,3-triazole moiety at the 5′ position of the nucleoside moiety. However, such modification has never been investigated as an internal modification of the 5′,5′-oligophosphate chain within the cap nor any other biologically active dinucleoside 5′,5′-oligophoosphate.
The inventors obtained a novel class of dinucleotide cap analogues that can be provided by a simpler and more efficient synthetic approach, based on click chemistry.35 The inventors employed copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) in aqueous medium to combine two 5′-mononucleotide subunits into one 5′,5′-dinucleotide cap analog containing substituted 1,2,3-triazole as an internal modification of the oligophosphate chain. The analogs vary in the oligophosphate chain length, positioning of the triazole moiety within the oligophosphate chain, and type of spacers linking phosphate groups to the triazole moiety. Optionally, the new analogs have also a 2-O or 3′-O-alkyl group within 7-methylguanosine preferably a methyl group, producing analogs called anti-reverse cap analogs (ARCA). All new analogs were synthesized in aqueous medium under standard CuAAC catalytic conditions (CuSO4, sodium ascorbate) from two chemically stable mononucleotide intermediates, in high yield, with formation of very little to no side-products. Several of the phosphotriazole analogues have high affinity for eukaryotic translation initiation factor 4E (eIF4E). mRNAs terminated with the new cap analogues can be obtained by standard in vitro transcription reaction. The efficiencies of cap incorporation into short RNA transcripts (% of capping) are comparable or slightly lower to those of unmodified caps. The short transcripts containing novel analogs are susceptible to decapping by Dcp2 decapping enzyme in vitro, thereby behaving like RNAs capped with unmodified cap structures. Surprisingly, luciferase-encoding mRNAs capped with some of the new phosphotriazole cap analogues had translational properties comparable to RNAs carrying standard 5′ caps, despite the presence of the bulky triazole group. This is in contrast to previously reported cap analogs containing less bulky bridging modifications of oligophosphate e.g. (O to NH or O to CH2 substitutions)10, 36, 37 or analogs containing a 1,2,3-triazole moiety at the 5′ position of the nucleoside moiety.45), which all have promoted translation less efficiently than standard cap analogs. Hence, the unexpected and unique property of phosphotriazole cap analogs is that they are good functional mimics of the natural cap. As such, phosphotriazole cap analogs are a viable alternative to the standard cap analogs that are obtained by more laborious chemical synthesis.
Therefore, the object of the invention is a compound of formula (I):
or a stereoisomer or salt thereof,
wherein R1 and R2 are selected from the group consisting of N, N+—CH3, N+—C2H5, N+—C3H8, N+—C4H5, N+—CH2C6H5 wherein at least one of R1, R2 is not N.
n and m are independently chosen from the group consisting of 0, 1 and 2;
X is selected from the group consisting of O, NH, S, CH2
k is 1 or 2
Y is either void or selected from the group of —CH2—, —CH2CH2—, —CH2O—, —CH2S—, —CH2NH—, —CH2CH2O—, —CH2CH2NH—, —CH2CH2S—
R3, R4, R5, R6 are selected from the group consisting of H, OH, OCH3, or OCH2CH3; wherein R3 and R4 may be the same or different; R5 and R6 may be the same or different; if either of R3, R4 is different than OH than R5 and R6 are both OH; if either of R5, R6 is different than OH than R3 and R4 are both OH.
In an embodiment of the compound according to the invention, R1 is N+—CH3, R3 and R4 are selected from the group consisting of OH and OCH3 and at least one of R3, R4 is not OH, R5 and R6 are both OH, n is at least 1.
In another embodiment of the compound according to the invention R2 is N+—CH3, R5 and R6 are selected from the group consisting of OH and OCH3 and at least one of R5, R6 is not OH, R3 and R4 are both OH, m is at least 1.
Preferably, the compound of the invention is selected from the group consisting of the following:
The object of the invention is also a composition comprising at least one of the compounds of the invention or at least one stereoisomer or salt thereof and a suitable carrier or diluent.
The object of the invention is also an RNA molecule whose 5′ end incorporates the compound of the invention.
The object of the invention is also a method of synthesizing, in vitro or in vivo, the RNA molecule of the invention, said method comprising reacting ATP, CTP, UTP, and GTP, the compound of the invention or the composition of the invention, and a polynucleotide template in the presence of RNA polymerase, in conditions enabling transcription by the RNA polymerase of the polynucleotide template into an RNA copy; whereby some of the RNA copies will incorporate the compound of the invention to make an RNA molecule of the invention.
The object of the invention is also a method of synthesizing a protein or peptide in vitro, said method comprising translating the RNA molecule of the invention in a cell-free protein synthesis system, wherein the RNA molecule comprises an open reading frame, in conditions enabling translation of the open reading frame of the RNA molecule into the protein or peptide encoded by the open reading frame.
The object of the invention is also a method of synthesizing a protein or peptide in vivo or in cultured cells, said method comprising translating the RNA molecule of the invention in vivo or in cultured cells, wherein the RNA molecule comprises an open reading frame, under conditions enabling translation of the open reading frame of the RNA molecule into the protein or peptide encoded by the open reading frame.
A further object of the invention is a use of the compound of the invention or the composition of the invention in an in vitro or in vivo synthesis of an RNA molecule.
A further object of the invention is a use of the RNA molecule of the invention in an in vitro or in vivo synthesis of a protein or peptide.
Phosphotriazole cap analogues were synthesized in CuAAC reactions between two “clickable” mononucleotide analogues, a guanine nucleotide containing a terminal alkyne within the phosphate chain and an appropriate azide-containing nucleotide (
Table 1. lists several phosphotriazole cap analogs that were synthesized and characterized by chemical, biophysical, biochemical, and molecular biology methods. It also shows the structures of mononucleotides used as starting materials for the synthesis, and the HPLC yields of the corresponding syntheses. Compounds that are particularly favorable for production of capped mRNAs include m7GppptC2H4NHpG, m7GpppCH2tC2H4NHpG, m27,2′-OGppptC2H4NHpG, m27,2′-OGppptC2H4NHppG, m27,2′-OGppptC2H4OppG, m27,2′-OGppptC2H4OpG, m27,2′-OGpptC2H4OppG.
The reactions were quenched with EDTA to ensure the effective removal of copper ions, which could otherwise interfere with subsequent biological experiments, and directly purified by reversed phase high-performance liquid chromatography (RP HPLC). All dinucleotide cap analogues were obtained in good-to-excellent yields (70-100%, usually exceeding 90%) and isolated in high purity. The starting materials were obtained in 2-3 step from commercially available starting materials (Sigma-Aldrich). Alkyne-containing C-phosphonate analogues were obtained by MgCl2-mediated coupling between triethylammonium salts of C-phosphonate subunits and guanosine mono- or diphosphate imidazolides, followed by N7-methylation by methyl iodide. Phosphoramidate analogues containing either an alkyne or azide moiety were synthesized by reacting propargylamine or 2-azidoethylamine and an appropriate guanine nucleotide imidazolide in aqueous buffer. Azide-containing phosphoester analogues were obtained either by MgCl2-mediated coupling between triethylammonium salts of azidoethyl phosphate subunit and guanosine monophosphate imidazolide or by the reaction between protected guanosine H-phosphonate and azidoethanol followed by removal of protecting groups.
1.1. Starting Materials and Chemical Reagents
All solvents and reagents were synthesis grade and used without further treatment, unless otherwise stated. C-phosphonate nucleotide analogues (GppC2H, GppC3H3, GppC4H5, GpppC2H, GpppC3H3, GpppC4H5),38 2′-O-methylguanosine 5′-monophosphate6,2-azidoethanamine39 and 2′,3′-O,O-isopropylideneguanosine46 were synthesized as described previously in the respective cited literature.
1.2. Chromatography
1.2.1. Ion-Exchange Chromatography
The synthesized mononucleotide analogues functionalized with either alkyne or azide group were purified by ion-exchange chromatography on DEAE Sephadex A-25 (HCO3− form) column. After loading the column with reaction mixture and washing it with water, the products were eluted using different gradients of TEAB in deionized water: 0-0.7 M for nucleoside monophosphates, 0-1.0 M for nucleoside diphosphates or 0-1.2 M nucleoside triphosphates. Fractions containing the desired product were collected together after RP HPLC and spectrophotometric analysis (at 260 nm). Evaporation under reduced pressure with repeated additions of 96% ethanol, then 99.8% ethanol and, at the end, MeCN resulted in isolation of nucleotide analogues as triethylammonium (TEA) salts.
1.2.2. Analytical and Preparative Reverse-Phase (RP) HPLC
Both analytical and semi-preparative HPLC were performed on Agilent Technologies Series 1200 with UV-detection at 254 nm and fluorescence detection (Ex: 260 nm, Em: 370 nm). For chemical and enzymatic reactions, monitoring analytical HPLC was performed using Supelcosil LC-18-T column (4.6×250 mm, 5 μm, flow rate 1.3 mL/min) with one of three different linear gradients of methanol in 0.05 M ammonium acetate buffer (pH 5.9): program A—gradient 0-25% of methanol in 15 min, program B—gradient 0-50% of methanol in 15 min, program C—gradient 0-50% of methanol in 7.5 min and then isocratic elution (50% of methanol) until 15 min. For pH-dependent degradation studies and reactions monitoring of different steps of ARCA analogues synthesis analytical HPLC was performed using Grace VisionHT C18-HL column (4.6×250 mm, 5 μm, flow rate 1.3 mL/min) with linear gradient 0-25% of methanol in 0.05 M ammonium acetate buffer (pH 5.9) in 15 min. Semi-preparative RP HPLC was performed using Discovery RP Amide C-16 HPLC column (25 cm×21.2 mm, 5 μm, flow rate 5.0 mL/min) with linear gradients of acetonitrile in 0.05 M ammonium acetate buffer (pH 5.9). The products, after at least triple lyophilisation, were isolated as ammonium salts.
Examplary results for RP HPLC analysis of CuAAC reaction leading to phosphotriazole cap analog are shown in
1.3. Yields and Concentrations Determination
The yields of mononucleotide analogues after ion-exchange purification and the concentrations of mono- and dinucleotide analogues solutions used for biophysical and biological experiments were determined on the basis of absorbance measurements performed at 260 nm in 0.1 M phosphate buffer pH 6.0 for 7-methylguanine mononucleotide analogues and in 0.1 M phosphate buffer pH 7.0 for dinucleotide analogues and guanine mononucleotide analogues. The quantities of obtained ion-exchange purified products were expressed as optical density miliunits (opt. mu=absorbance of the solution by volume in mL). For calculations of yields and concentrations following molar extinction coefficients [M−1cm−1] were employed: ε=22600 (dinucleotides), ε=11400 (m7G mononucleotides), ε=12080 (G mononucleotides). Concentrations of transcripts were determined using NanoDrop 2000c Spectrofotometer (Thermo Scientific).
1.4. NMR Spectroscopy and Mass Spectrometry
The structure and purity of each final product were confirmed by high resolution mass spectrometry using negative or positive electrospray ionization (HRMS (−) ESI or HRMS (+) ESI) and 1H NMR, 31P NMR, gDQCOSY and gHSQCAD spectroscopy. Mass spectra were recorded on Thermo Scientific LTQ OrbitrapVelos spectrometer. NMR spectra were recorded on a Varian INOVA 400 MHz or 500 MHz spectrometer equipped with a high stability temperature unit using 5 mm 4NUC probe, at 25° C. if not stated otherwise, at 399.94/500.61 MHz (1H NMR) and 161.90/202 MHz (31P NMR). The 1H NMR and 31P NMR chemical shifts were reported in ppm and referenced to respective internal standards: sodium 3-(trimethylsilyl)-2,2′,3,3′ tetradeuteropropionate (TSP) and 20% phosphorus acid in D2O. Signals in 1H NMR spectra of dinucleotides were assigned according to 2D NMR spectra (gDQCOSY, gHSQCAD). In 31P signal assignment of dinucleotide cap analogues the phosphates were denoted analogously to m7G(pδ)pγpβp60G.
Some cap analogues hydrolyzed in D2O gradually. Although pure compounds (see HPLC profiles, Supporting Information 2) were dissolved in D2O just before measurements, the spectra indicated some level of hydrolysis. % of hydrolysis is provided along with compound characterization data, if higher than 5%.
1.5. Synthesis of Nucleotide Imidazolide Derivatives
1.5.1. Preparation of Compounds for Imidazole-Activation
Preparation of Triethylammonium (TEA) Salts
The commercially available guanosine 5′-monophosphate (GMP) disodium salt and tetrasodium pyrophosphate were converted into triethylammonium forms by passing their aqueous solutions (ca. 1 g/20 mL) through Dowex 50 W×8 cationite. The collected eluates were evaporated under reduced pressure with repeated additions of ethanol and acetonitrile to dryness yielding the nucleotide triethylammonium salt as a white solid and triethylammonium pyrophosphate as colorless oil.
Triethylammonium phosphate was prepared by slowly adding triethylamine to the low-concentrated solution of H2PO4 in water until pH 7 was obtained which was followed by evaporation to afford oily, colorless residue.
Synthesis of Guanosine 5′-Diphosphate (GDP), Guanosine 5′-Triphosphate (GTP) and 2′-O-Methylguanosine 5′-Diphosphate (m2′-OGDP)
Triethylammonium phosphate (4 equiv.) or triethylammonium pyrophosphate (4 equiv.) was suspended in DMF (ca. 0.4 M) in the presence of ZnCl2 (4 equiv.) and stirred for ˜5 min to obtain a solution. Then, GMP-Im or m2′-OGMP-Im (1 equiv.) along with a second portion of ZnCl2 (4 equiv.) was added and the mixture was stirred for 1-2 h at room temperature. The reaction was stopped by 10-fold dilution with water and addition of EDTA (8 equiv.) and NaHCO3 (ca. 17.6 equiv.). The ion-exchange purification afforded triethylammonium salt of GDP (64%), GTP (79%) and m2′-OGDP (95%).
N7-Methylation of Guanine Nucleotides (GMP, GDP and GTP)
An appropriate analogue (GMP, GDP or GTP, TEA salt) was dissolved in dry DMSO to obtain ca. 0.1 M solution followed by addition of CH3I (8 equiv.). The mixture was stirred at room temperature for several hours until HPLC analysis indicated more than 90% conversion of the substrate and the presence of N7-methylated nucleotide as the major product. The reaction was stopped by 10-fold dilution with water and organic-soluble compounds were removed by 3-time washing with diethyl ether. The aqueous phase was then treated with a pinch of Na2S2O5 to reduce the residual iodine and the pH of solution was set to 7 by addition of solid NaHCO3. The following ion-exchange purification afforded triethylammonium salt of m7GMP (63%), m7GDP (68%) or m7GTP (58%).
1.5.2. Activation with Imidazole
Synthesis of Nucleotide Imidazolides
Compounds were prepared according to Mukaiyama and Hashimoto.40 An appropriate nucleotide (1 eq., TEA salt), imidazole (10 equiv.), 2,2′-dithiodipyridine (3 equiv.) were mixed in DMF (˜2.5 mL/100 mg of nucleotide) before addition of triethylamine (3 equiv.) and triphenylphosphine (3 equiv.). The mixture was stirred for 6-8 h at room temperature. The addition of a solution of anhydrous NaClO4 (4 equiv.) in dry acetone (˜8 volumes of DMF volume) resulted in precipitation of the product as sodium salt. The suspension was cooled at 4° C. and the precipitate was filtered off, washed repeatedly with cold, dry acetone and dried in vacuum over P4O10. Yields 90-100%.
1.6. Synthesis of m7G C-Phosphonate Nucleotide Analogues
General Procedure B (GP B): N7-Methylation of Guanine Nucleotides Using CH3I
An appropriate nucleotide (TEA salt) was dissolved in dry DMSO to obtain ca. 0.1 M solution followed by addition of CH3I (8 equiv.). The mixture was stirred at room temperature for several hours until HPLC analysis indicated more than 90% conversion of the substrate and the presence of N7-methylated nucleotide as the major product. The reaction was stopped by 10-fold dilution with water and organic-soluble compounds were removed by 3-time washing with diethyl ether. The aqueous phase was then treated with a pinch of Na2S2O5 to reduce the residual iodine and the pH of solution was set to 7 by addition of solid NaHCO3. The product was purified by ion-exchange chromatography on DEAE Sephadex A-25 and evaporated to dryness as described in General Information. Prior to NMR characterization the product was additionally purified by semi-preparative HPLC as described in General Information.
General Procedure C (GP C): N7-Methylation of Guanine Nucleotides Using (CH3)2SO4
An appropriate nucleotide (TEA salt) was dissolved at ˜0.2 M concentration in ca. 0.5 mM aqueous CH3COOH (pH 4) to obtain ca. 0.2 M solution. Then, 5 portions of (CH3)2SO4 (2 equiv. each) were added every 10 min to the mixture under vigorous stirring and the pH was maintained at 4 by adding 10% KOH if necessary. The stirring was continued at room temperature for several hours until HPLC analysis indicated more than 90% conversion of the substrate and the presence of N7-methylated nucleotide as the major product. The reaction was stopped by 10-fold dilution with water and organic-soluble compounds were removed by 3-time washing with diethyl ether. The pH of aqueous phase was then set to 7 by addition of solid NaHCO3. The product was purified by ion-exchange chromatography on DEAE Sephadex A-25 and evaporated to dryness as described in General Information. Prior to NMR characterization the product was additionally purified by semi-preparative HPLC as described in General Information.
β-C-(2-Ethynyl), β-C-(2-Propargyl) and β-C-(3-Butynyl) Guanosine Diphosphate and γ-C-(2-Ethynyl), γ-C-(2-Propargyl) and γ-C-(3-Butynyl) Guanosine Triphosphate Triethylammonium Salts (GppC2H, GppC3H3, GppC4H5, GpppC2H, GpppC3H3, GpppC4H5)
Compounds were obtained according to Wanat et al.38 Briefly, triethylammonium 3-butynyl C-phosphonate, tributylammonium 3-trimethylsilyl-1-propargyl C-phosphonate or triethylammonium 2-ethynyl C-phosphonate (each 2.5 equiv.) was stirred in DMF (ca. 0.4 M) until complete dissolution. Then, an appropriate nucleotide imidazolide (1 equiv.) along with MgCl2 (8 equiv.) were added and the mixture was stirred for 1-2 h at room temperature. The reaction was stopped by 10-fold dilution with water. The product was purified by ion-exchange chromatography on DEAE Sephadex A-25 and evaporated to dryness as described in General Information to afford products in a form of triethylammonium salts. Trimethylsililpropargylophosphonate nucleotide analogues were then deprotected by incubation in TBAF/THF (1 M):ACN (1:3, v/v) mixture (1.1 equiv. of TBAF per nucleotide) at room temperature for 24 h. After removing the solvent under reduced pressure, the crude product was directly subjected to click reactions. Yields: 45-90%.
β-C-(3-Butynyl) 7-Methylguanosine Diphosphate Ammonium Salt (m7GppC4H5)
Obtained according to GP B starting from β-C-(3-butynyl) guanosine diphosphate triethylammonium salt (11000 mOD, 0.910 mmol), CH3I (0.454 mL, 7.285 mmol) and DMSO (9.0 mL). The ion-exchange purification afforded 7061 mOD (0.619 mmol, 68%) of m7GppC4H5 triethylammonium salt. Additional HPLC purification of a fraction of obtained product gave m7GppC4H5 as ammonium salt.
1H NMR (400 MHz, D2O, 25° C.) δH: 9.21 (1H, s, H8), 6.08 (1H, d, J1′-2′=3.6, H1′), 4.70 (1H, dd, J1′-2′=3.6, J2′-3′=4.7, H2′), 4.51 (1H, dd, J2′-3′=4.7, J3′-4′=5.5, H3′), 4.39-4.43 (1H, m, H4′), 4.34 (1H, ddd, J5′-5″=12.0, J=4.2, 2.5, H5′), 4.22 (1H, ddd, J5′-5″=12.0, J=5.2, 2.2, H5″), 4.13 (3H, s, m7), 2.46 (2H, dtd, JCH2(C2H)—CH=2.6, JCH2(C2H)—CH2(P)=8.1, JCH2(C2H)—Pβ=10.1, HCH2(C2H)), 2.34 (1H, t, JCH—CH2(C2H)=2.6, HCH), 1.94 (2H, dt, JCH2(C2H)—CH2(P)=8.1, JCH2(P)—Pβ=16.9, HCH2(P)); 31P NMR (162 MHz, D2O, 25° C.) δP: 16.45 (1P, dtt, JCH2(C2H)—Pβ=10.1, JCH2(P)—Pβ=16.9, JPα-Pβ=26.6, Pβ), −11.34 (1P, br d, JPα-Pβ=26.6, Pα); HRMS (−) ESI m/z found: 492.0692, calc. for C15H20N5O10P2−: 492.0685.
γ-C-(3-Butynyl) 7-Methylguanosine Triphosphate Ammonium Salt (m7GpppC4H5)
Obtained according to GP B starting from γ-C-(3-butynyl) guanosine triphosphate triethylammonium salt (GpppC4H5) (11000 mOD, 0.910 mmol), CH3I (0.454 mL, 7.285 mmol) and DMSO (9.0 mL). The ion-exchange purification afforded 7677 mOD (0.673 mmol, 74%) of m7GpppC4H5 triethylammonium salt. Additional HPLC purification of a fraction of obtained product gave m7GpppC4H5 as ammonium salt.
1H NMR (400 MHz, D2O, 25° C.) δH: 9.23 (1H, s, H8), 6.08 (1H, d, J1′-2′=3.5, H1′), 4.69 (1H, dd, J1′-2′=3.5, J2′-3′=4.7, H2′), 4.54 (1H, dd, J2′-3′=4.7, J3′-4′=5.5, H3′), 4.35-4.42 (2H, overlapped H4′ and H5′), 4.26 (1H, ddd, J5′-5″=12.0, J=5.2, 1.7, H5″), 4.13 (3H, s, m7), 2.44 (2H, dtd, JCH—CH2(C2H)=2.5, JCH2(P)—CH2(C2H)=8.3, JCH2(C2H)—Pγ=11.2, HCH2(C2H)), 2.26 (1H, t, JCH—CH2(C2H)=2.5, HCH), 1.99 (2H, dt, JCH2(P)—CH2(C2H)=8.3, JCH2(P)—Pγ=16.7, HCH2(P)); 31P NMR (162 MHz, D2O, 25° C.) δP: 16.46 (1P, dtt, JCH2(C2H)—Pγ=11.2, JCH2(P)—Pγ=16.7, JPβ-Pγ=25.0, Pγ), −11.47 (1P, br d, JPα-Pβ=19.2, Pα), −23.10 (1P, dd, JPα-Pβ=19.2, JPβ-Pγ=25.0, Pβ); HRMS (−) ESI m/z found: 572.0357, calc. for C15H21N5O13P3−: 572.0349.
β-C-(2-Propargyl) 7-Methylguanosine Diphosphate Ammonium Salt (m7GppC3H3)
Obtained according to GP B starting from β-C-(2-propargyl) guanosine diphosphate triethylammonium salt (8310 mOD, 0.688 mmol), CH3I 0.343 mL, 5.503 mmol) and DMSO (7.0 mL). The ion-exchange purification afforded 4706 mOD (0.413 mmol, 60%) of m7GppC3H3 triethylammonium salt. Additional HPLC purification of a fraction of obtained product gave m7GppC3H3 as ammonium salt.
1H NMR (400 MHz, D2O, 25° C.) δH: 6.06 (1H, d, J1′-2′=3.5, H1′), 4.68 (1H, dd, J1′-2′=3.5, J2′-3′=5.0, H2′), 4.50 (1H, dd, J2′-3′=5.0, J3′-4′=5.5, H3′), 4.40-4.42 (1H, m, H4′), 4.36 (1H, ddd, J5′-5″=11.8, J=4.0, 2.4, H5′), 4.23 (1H, ddd, J5′-5″=11.8, J=5.4, 2.0, H5″), 4.12 (3H, s, m7), 2.76 (2H, dd, JCH2-Pβ=21.4, JCH2-CH=2.7, HCH2), 2.34 (1H, dt, JCH—CH2=2.7, JCH—Pβ=6.5, HCH); 31P NMR (162 MHz, D2O, 25° C.) δP: 9.44 (1P, dtd, JPα-Pβ=24.2, JCH2-Pβ=21.4, JCH—Pβ=6.5, Pβ), −10.76 (1P, br d, JPα-Pβ=24.2, Pα); HRMS (−) ESI m/z found: 478.0521, calc. for C14H18N5O10P2−: 478.0529.
γ-C-(2-Propargyl) 7-Methylguanosine Triphosphate Ammonium Salt (m7GpppC3H3)
Obtained according to GP B starting from γ-C-(2-propargyl) guanosine triphosphate triethylammonium salt (10000 mOD, 0.828 mmol), CH3I (0.412 mL, 6.622 mmol) and DMSO (8.0 mL). The ion-exchange purification afforded 6324 mOD (0.555 mmol, 67%) of m7GppC3H3 triethylammonium salt. Additional HPLC purification of a fraction of obtained product gave 11d as ammonium salt.
1H NMR (400 MHz, D2O, 25° C.) δH: 6.06 (1H, d, J1′-2′=3.49, H1′), 4.69 (1H, dd, J1′-2′=3.49, J2′-3′=4.73, H2′), 4.53 (1H, dd, J2′-3′=4.73, J3′-4′=5.48, H3′), 4.35-4.42 (1H, overlapped H4′ and H5′), 4.24-4.28 (1H, ddd, J5′-5″=11.7, J=5.2, 2.0, H5″), 4.13 (3H, s, m7), 2.78 (2H, dd, JCH2-Pγ=21.7, JCH2-CH=2.5, HCH2), 2.34 (1H, dt, JCH2-CH=2.5, JCH—Pγ=6.5, HCH); 31P NMR (162 MHz, D2O, 25° C.) δP: 9.38 (1P, dtd, JCH2-Pγ=21.7, JPβ-Pγ=23.9, JCH—Pγ=6.5, Pγ), −10.85 (1H, br d, JPα-Pβ=19.2, Pα), −22.50 (1P, dd, JPα-Pβ=19.2, JPβ-Pγ=23.9, Pβ); HRMS (−) ESI m/z found: 558.0184, calc. for C14H19N5O13P3−: 558.0192.
β-C-(2-Ethynyl) 7-Methylguanosine Diphosphate Ammonium Salt (m7GppC2H)
Obtained according to GP C starting from β-C-(2-ethynyl) guanosine diphosphate triethylammonium salt (10000 mOD, 0.828 mmol), (CH3)2SO4 (0.785 mL, 8.278 mmol) and CH3COOH solution pH 4 (8.0 mL). The ion-exchange purification afforded 4814 mOD (0.422 mmol, 51%) of m7GppC2H triethylammonium salt. Additional HPLC purification of a fraction of obtained product gave m7GppC2H as ammonium salt.
1H NMR (400 MHz, D2O, 25° C.) δH: 6.08 (1H, d, J1′-2′=3.7, H1′), 4.70 (1H, dd, J1′-2′=3.7, J2′-3′=4.7, H2′), 4.51 (1H, dd, J2′-3′=4.7, J3′-4′=5.5, H3′), 4.41-4.44 (1H, m, H4′), 4.38 (1H, ddd, J5′-5″=11.7, J=4.3, 2.4, H5′), 4.24 (1H, ddd, J5′-5″=11.7, J=5.3, 2.2, H5″), 4.13 (3H, s, m7), 3.20 (1H, d, JPγ-C2H=11.6, HC2H); 31P NMR (162 MHz, D2O, 25° C.) δP: −10.58 (1P, br d, JPα-Pβ=22.0, Pα), −20.86 (1P, dd, JPγ-Pβ=22.0, JPγ-C2H=11.6, Pβ); HRMS (−) ESI m/z found: 464.0378, calc. for C13H16N5O10P2−: 464.0372.
γ-C-(2-Ethynyl) 7-Methylguanosine Triphosphate Ammonium Salt (m7GpppC2H)
Obtained according to GP B starting from γ-C-(2-ethynyl) guanosine triphosphate triethylammonium salt (10000 mOD, 0.828 mmol), (CH3)2SO4 (0.785 mL, 8.278 mmol) and CH3COOH solution pH 4 (8.0 mL). The ion-exchange purification afforded 5569 mOD (0.488 mmol, 59%) of m7GpppC2H triethylammonium salt. Additional HPLC purification of a fraction of obtained product gave m7GpppC2H as ammonium salt.
1H NMR (400 MHz, D2O, 25° C.) δH: 6.08 (1H, d, J1′-2′=3.9, H1′), 4.70 (1H, dd, J1′-2′=3.9, J2′-3′=4.9, H2′), 4.54 (1H, dd, J2′-3′=4.7, J3′-4′=5.3, H3′), 4.41-4.44 (1H, m, H4′), 4.38 (1H, ddd, J5′-5″=11.7, J=4.1, 2.5, H5′), 4.24 (1H, ddd, J5′-5″=11.7, J=5.1, 2.0, H5″), 4.14 (3H, s, m7), 3.18 (1H, d, J=12.9, HC2H); 31P NMR (162 MHz, D2O, 25° C.) δP: −10.80 (1P, br d, JPα-Pβ=20.5, Pα), −21.02 (1P, dd, JPγ-Pβ=20.5, JPγ-C2H=11.7, Pγ), −22.93 (1P, t, JPα-Pβ=JPγ-Pβ=20.5, Pβ); HRMS (−) ESI m/z found: 544.0042, calc. for C13H17N5O13P3−: 544.0036.
β-C-(2-Ethynyl) 2′-O-Methylguanosine Diphosphate Triethylammonium Salt m2′-OGppC2H
Triethylammonium 2-ethynyl C-phosphonate (1.053 mmol, 0.35 M) was stirred in 3 mL DMF until complete dissolution. Then, 2′-O-methylguanosine 5′-monophosphate P-imidazolide sodium salt (4241 mOD, 0.35 mmol) along with MgCl2 (268 mg, 2.8 mmol) were added and the mixture was stirred for 0.5 h at room temperature. The reaction was stopped by 10-fold dilution with water. The product was purified by ion-exchange chromatography on DEAE Sephadex A-25 and evaporated to dryness as described in General Information to afford 3647 mOD, (0.302 mmol, 86%) of m2′-OGppC2H triethylammonium salt. Additional HPLC purification of a fraction of obtained product gave m2′-OGppC2H as ammonium salt.
1H NMR (500 MHz, Deuterium Oxide) δ 8.14 (s, 1H, H8), 5.93 (d, J=6.5 Hz, 1H, H1′), 4.85 (dd, J=6.5, 5.2 Hz, 1H, H2′), 4.59 (dd, J=5.2, 3.0 Hz, 1H, H3′), 4.40-4.35 (m, 1H, H4′), 4.28 (ddd, J=11.5, 6.0, 3.4 Hz, 1H, H5′), 4.22 (ddd, J=11.5, 4.9, 3.5 Hz, 1H), 3.18 (d, J=12.9 Hz, 1H, HC2H); 31P NMR (202 MHz, Deuterium Oxide) δ −10.58 (dt, J=18.7, 6.0 Hz, 1P, Pα), −20.84 (dd, J=18.6, 12.9 Hz, 1P, Pδ), −22.53 (t, J=18.0 Hz, 1P, Pβ or Pγ), −23.04 (t, J=18.0 Hz, 1P, Pβ or Pγ); HRMS (−) ESI m/z found: 464.0379, calc. for: C13H16N5O10P2− 464.0378.
γ-C-(2-Ethynyl) 2′-O-Methylguanosine Triphosphate Triethylammonium Salt (m2′-OGpppC2H)
Triethylammonium 2-ethynyl C-phosphonate (1.698 mmol, 0.2 M) was stirred in 8.5 mL DMF until complete dissolution. Then, 2′-O-methylguanosine 5′-diphosphate β-P-imidazolide trisodium salt (6842 mOD, 0.566 mmol) along with MgCl2 (431 mg, 4.531 mmol) were added and the mixture was stirred for 1 h at room temperature. The reaction was stopped by 10-fold dilution with water. The product was purified by ion-exchange chromatography on DEAE Sephadex A-25 and evaporated to dryness as described in General Information to afford 6385 mOD (0.528 mmol, 93%) of m2′-OGpppC2H triethylammonium salt. Additional HPLC purification of a fraction of obtained product gave m2′-OGpppC2H as ammonium salt.
1H NMR (400 MHz, D2O, 25° C.) δH: 8.13 (1H, s, H8), 5.99 (1H, d, J1′-2′=6.5, H1′), 4.74 (1H, dd, J2′-3′=5.1, J3′-4′=3.1, H3′), 4.56 (1H, dd, J2′-3′=5.1, J1′-2′=6.5, H2′), 4.36-4.39 (1H, m, H4′), 4.28 (1H, ddd, J5′-5″=11.7, JPα-5′=5.9, J4′-5′=3.5, H5′), 4.24 (1H, ddd, J5′-5″=11.7, J4′-5″=5.1, JPα-5″=3.4, H5″), 3.47 (3H, s, m2′O), 3.18 (1H, d, JC2H—Pγ=13.1, HC2H); 31P NMR (162 MHz, D2O, 25° C.) δP: −10.80 (1P, ddd, JPα-Pβ=20.5, JPα-5′=5.9, JPα-5″=3.4, Pα), −21.02 (1P, dd, JC2H—Pγ=13.1, JPβ-Pγ=19.1, Pγ), −22.99 (1P, dd, JPβ-Pγ=10.1, JPα-Pβ=20.5, Pβ); HRMS (−) ESI m/z found: 544.0044, calc. for C13H17N5O13P3−: 544.0036.
β-C-(2-Ethynyl) 2′-O—N7-Dimethylguanosine Diphosphate Ammonium Salt (m27,2′-OGppC2H)
Obtained according to GP C starting from β-C-(2-ethynyl) 2′-O′methylguanosine diphosphate triethylammonium salt (3100 mOD, 0.257 mmol), (CH3)SO4 (0.292 mL, 3.08 mmol) and CH3COOH solution pH 4 (3.1 mL). The ion-exchange purification afforded 2180 mOD, (0.191 mmol, 74%) of m27,2′-OGppC2H triethylammonium salt. Additional HPLC purification of a fraction of obtained product gave m27,2′-OGppC2H as ammonium salt.
1H NMR (500 MHz, Deuterium Oxide) δ 6.16 (d, J=3.5 Hz, 1H, H1′), 4.62 (t, J=4.9, 5.5 Hz, 1H, H3′), 4.41 (dd, J=4.9, 3.5 Hz, 1H, H2′), 4.40-4.38 (m, 1H, H4′), 4.36 (ddd, J=11.8, 4.3, 2.4 Hz, 1H, H5′), 4.23 (ddd, J=11.8, 5.2, 2.1 Hz, 1H, H5″), 4.13 (s, 3H, m7), 3.60 (s, 3H, m2′O), 3.19 (d, J=12.5 Hz, 1H, C2H); 31P NMR (202 MHz, Deuterium Oxide) δ −11.00 (dt, J=22.1, 4.5 Hz, 1P, Pα), −20.80 (dd, J=22.1, 12.5 Hz, 1P, Pβ); HRMS (−) ESI m/z found: 478.0537, calc. for: C14H18N5O10P2− 478.0534.
γ-C-(2-Ethynyl) 2′-O—N7-Dimethylguanosine Triphosphate Ammonium Salt (m27,2′-OGpppC2H)
Obtained according to GP C starting from γ-C-(2-ethynyl) 2′-O′methylguanosine triphosphate triethylammonium salt (5380 mOD, 0.445 mmol), (CH3)SO4 (0.422 mL, 4.454 mmol) and CH3COOH solution pH 4 (5.0 mL). The ion-exchange purification afforded 4014 mOD (0.352 mmol, 79%) of m27,2′-OGpppC2H triethylammonium salt. Additional HPLC purification of a fraction of obtained product gave m27,2′-OGpppC2H as ammonium salt.
1H NMR (400 MHz, D2O, 25° C.) δH: 6.16 (1H, d, J1′-2′=3.1, H1′), 4.65 (1H, dd, J=5.1, 5.5, H3′), 4.36-4.42 (3H, overlapped H2′, H4′ and H5′), 4.26 (1H, ddd, J5′-5″=12.5, JPα-5″=4.8, J4′-5″=2.7, H5″), 4.14 (3H, s, m7), 3.61 (3H, s, m2′O), 3.18 (1H, d, JPγ-C2H=12.9, HC2H); 31P NMR (162 MHz, D2O, 25° C.) δP: −10.80 (1P, ddd, JPα-Pβ=20.5, JPα-5′=7.3, JPα-5″=4.8, Pα), −21.05 (1P, dd, JPβ-Pγ=19.1, JPγ-C2H=12.9, Pγ), −22.91 (1P, dd, JPβ-Pγ=19.1, JPα-Pβ=20.5, Pβ); HRMS (−) ESI m/z found: 558.0200, calc. for C14H19N5O13P3−: 558.0192.
1.7. Synthesis of Phosphoramidate Nucleotide Analogues
General Procedure D (GP D): Coupling of Nucleotide Imidazolides with Amine Linker
Compounds were synthesized analogously as described in Guranowski et al. for the reaction of diamine linkers with guanosine 5′-phosphorimidazolide.41 An appropriate nucleotide imidazolide was dissolved in 0.1 M Tris-HCl buffer pH 8.0 (approx. 1 mL per 100 mg nucleotide) and propargylamine or 2-azidoethyloamine (8 equiv.) was added. The mixture was stirred at room temperature for 24 h. The reaction was diluted with ten volumes of water and washed with diethyl ether. After setting pH to 7 with 5% HCl, the aqueous phase was either subjected to ion-exchange chromatography purification as described in General Information to afford the desired product as triethylammonium salt or directly purified by semi-preparative HPLC to afford the desired product as ammonium salt.
1.7.1. Synthesis of Azide-Modified Phosphoramidate Nucleotide Analogues
N-(2-Azidoethyl) Phosphoramidate Guanosine Monophosphate Ammonium Salt (GpNHC2H4N3)
Obtained according to GP D starting from guanosine 5′-monophosphate P-imidazolide sodium salt (200 mg, 4800 mOD, 0.397 mmol), 2-azidoethylamine (0.349 mL, 3.179 mmol) and 2.0 mL of Tris-HCl buffer. The ion-exchange purification afforded 4004 mOD (0.331 mmol, 83%) of GpNHC2H4N3 triethylammonium salt. Additional HPLC purification of a fraction of obtained product gave GpNHC2H4N3 as ammonium salt.
1H NMR (400 MHz, D2O, 25° C.) δH: 8.11 (1H, s, H8), 5.93 (1H, d, J1′-2′=5.9, H1′), 4.84 (1H, dd, J1′-2′=5.9, J2′-3′=5.1, H2′), 4.51 (1H, dd, J2′-3′=5.1, J3′-4′=3.9, H3′), 4.31-4.34 (1H, m, H4′), 4.04 (1H, ddd, J5′-5″=11.7, J=4.7, 3.1, H5′), 4.00 (1H, ddd, J5′-5″=11.7, J=5.1, 3.5), 3.24 (2H, br t, JCH2(N3)-CH2(NH)=5.9, HCH2(N3)), 2.89 (2H, dt, JCH2(N3)-CH2(NH)=5.9, JCH2(N3)-Pα=10.2, HCH2(NH)); 31P NMR (162 MHz, D2O, 25° C.) δP: 9.37-9.55 (1P, m, Pα); HRMS (−) ESI m/z found: 430.0991, calc. for C12H17N9O7P−: 430.0989.
N-(2-Azidoethyl) β-Phosphoramidate Guanosine Diphosphate Ammonium Salt (GppNHC2H4N3)
Obtained according to GP D starting from guanosine 5′-diphosphate β-P-imidazolide disodium salt (458 mg, 8244 mOD, 0.682 mmol), 2-azidoethylamine (0.600 mL, 5.460 mmol) and 4.5 mL of Tris-HCl buffer. The ion-exchange purification afforded 7085 mOD (0.586 mmol, 86%) of GppNHC2H4N3 triethylammonium salt. Additional HPLC purification of a fraction of obtained product gave GppNHC2H4N3 as ammonium salt.
1H NMR (400 MHz, D2O, 25° C.) δH: 8.12 (1H, s, H8), 5.93 (1H, d, J1′-2′6.3, H1′), 4.80 (1H, overlapped with HDO, H2′), 4.53 (1H, dd, J=3.7, 5.3, H3′), 4.33-4.36 (1H, m, H4′), 4.18-4.21 (1H, m, H5′ and H5″), 3.32 (2H, br t, JCH2(N3)-CH2(NH)=5.9, HCH2(N3)), 3.03 (2H, dt, JCH2(N3)-CH2(NH)=5.9, JCH2(N3)-Pβ=10.4, HCH2-NH); 31P NMR (162 MHz, D2O, 25° C.) δP: −1.04 (1P, dt, JCH2(N3)-Pβ=10.4, JPα-Pβ=22.0, Pβ), −10.26 (1P, br d, JPα-Pβ=22.0, Pα); HRMS (−) ESI m/z found: 510.0657, calc. for C12H18N9O10P2−: 510.0652; hydrolysis in D2O: 15%.
N-(2-Azidoethyl) Phosphoramidate 7-Methylguanosine Monophosphate Ammonium Salt (m7GpNHC2H4N3)
Obtained according to GP D starting from 7-methyl guanosine 5′-monophosphate P-imidazolide sodium salt (450 mg, 9900 mOD, 0.868 mmol), 2-azidoethylamine (0.764 mL, 6.944 mmol) and 4.5 mL of Tris-HCl buffer. The directly following HPLC purification afforded 3520 mOD of m7GpNHC2H4N3 (0.309 mmol, 36%) as ammonium salt.
1H NMR (400 MHz, D2O, 25° C.) δH: 6.08 (1H, d, J1′-2′=3.9, H1′), 4.68 (1H, dd, J1′-2′=3.9, J2′-3′=4.9, H2′), 4.48 (1H, dd, J2′-3′4.9, J3′-4′=5.4, H3′), 4.38-4.41 (1H, m, H4′), 4.18 (1H, ddd, J5′-5″=11.7, J=4.4, 2.4, H5′), 4.12 (3H, s, m7), 4.06 (1H, ddd, J5′-5″=11.7, J=4.9, 2.9, H5″), 3.35 (2H, t, JCH2(N3)-CH2(NH)=5.9, HCH2(N3)), 3.0 (2H, dt, JCH2(N3)-CH2(NH)=5.9, JPα-CH2(NH)=10.3, HCH2(NH)); 31P NMR (162 MHz, D2O, 25° C.) δP: 9.32-9.44 (1P, m, Pα); HRMS (−) ESI m/z found: 444.1146, calc. for C13H19N9O7P−: 444.1145.
N-(2-Azidoethyl) β-Phosphoramidate 7-Methylguanosine Diphosphate Ammonium Salt (m7GppNHC2H4N3)
Obtained according to GP D starting from 7-methylguanosine 5′-diphosphate β-P-imidazolide disodium salt (238 mg, 3641 mOD, 0.319 mmol), 2-azidoethylamine (0.281 mL, 2.555 mmol) and 2.5 mL of Tris-HCl buffer. The ion-exchange purification afforded 1785 mOD (0.156 mmol, 49%) of m7GppNHC2H4N3 triethylammonium salt. Additional HPLC purification of a fraction of obtained product gave m7GppNHC2H4N3 as ammonium salt.
1H NMR (400 MHz, D2O, 25° C.) δH: 6.08 (1H, d, J1′-2′=3.5, H1′), 4.68 (1H, dd, J1′-2′=3.5, J2′-3′=4.7, H2′), 4.51 (1H, J2′-3′=4.7, J3′-4′=5.5, H3′), 4.39-4.42 (1H, m, H4′), 4.34 (1H, ddd, J5′-5″=12.1, J=4.3, 2.4, H5′), 4.22 (1H, ddd, J5′-5″=12.1, J=5.5, 2.4, H5″), 4.13 (3H, s, m7), 3.41 (2H, t, JCH2(N3)-CH2(NH)=5.9, HCH2(N3)), 3.10 (2H, dt, JCH2(N3)-CH2(NH)=5.9, JCH2(NH)—Pβ=10.5, HCH2(NH)); 31P NMR (162 MHz, D2O, 25° C.) δP: −0.82 (1P, dt, JCH2-Pβ=10.5, JPα-Pβ=22.7, Pβ), −10.28 (1P, br d, JPα-Pβ=22.7, Pα); HRMS (−) ESI m/z found: 524.0819, calc. for C13H20N9O10P2: 524.0808.
1.8 Synthesis of Azide-Containing Phosphoester Analogues
Azidoethyl Phosphate
H3PO3 (50 mg, 0.610 mmol, 1 equiv.) was added to a flask and dissolved in 2-azidoethanol (1.385 ml, 18.293 mmol, 30 equiv.). Then, TEA (253 μl, 1.819 mmol, 3 equiv.) was added and the mixture was stirred for 5 min. Next, iodine (308 mg, 1.22 mmol, 2 equiv.) was gradually added and the mixture was stirred for 96 h at room temperature. The product was precipitated upon addition of the mixture of 350 μl of cyclohexylamine in 15.8 mL acetone. The precipitate was filtered off, washed repeatedly with cold, dry acetone until it turned white and then dried in vacuum over P2O5.
31P NMR (202 MHz, Deuterium Oxide) δ 4.10 (t, J=6.2 Hz).
2′,3′-O,O-Isopropylideneguanosine H-Phosphonate 2′3′-iPr-GpH
2′,3′-O,O-isopropylideneguanosine H-phosphonate was synthesized by stirring 2′,3′-O,O-isopropylideneguanosine (1.010 g, 3.128 mmol, 1 equiv.) with PCl3 (312 μl, 3.567 mmol, 1.1 equiv.) in the presence of 15.24 mL of trimethyl phosphate at 0° C. for 1 h. Then the mixture was diluted with approx. 150 ml of water and the pH was set to 7 using solid NaHCO3. The ion-exchange purification afforded 17760 mOD, (1.470 mmol, 47%) of 2′3′-iPr-GpH triethylammonium salt.
O-(2-Azidoethyl) Guanosine Phosphate Ammonium Salt (GpOC2H4N3)
To the flask containing 2′3′-iPr-GpH (3000 mOD, 0.248 mmol, 1 equiv.) BSA (607 μl, 2.48 mmol, 10 equiv.) and ACN (607 μl) were added. The mixture was stirred for 15 min after which TEA (102 μl, 0.744 mmol, 3 equiv.) along with 2-azidoethanol (564 μl, 7.44 mmol, 30 equiv.) were added and the stirring was continued for 5 min. Next, iodine (126 mg, 0.496 mmol, 2 equiv.) was gradually added and the reaction was stirred for 7 days at 45° C. After that, it was diluted with approx. 30 mL of water and the pH was set to 1.5 with conc. HCl. The resulting mixture was stirred at 60° C. for 1.5 h and then the pH was set to 7 with solid NaHCO3. The mixture was subjected to ion-exchange purification which afforded 1350 mOD (0.112 mmol, 45%) of GpOC2H4N3 triethylammonium salt. Additional HPLC purification of a fraction of obtained product gave GpOC2H4N3 as ammonium salt.
1H NMR (500 MHz, Deuterium Oxide) δ 8.20 (s, 1H, H8), 5.95 (d, J=5.4 Hz, 1H, H1′), 4.81 (dd, J=5.3, 5.4 Hz, 1H, H2′, overlapped with HDO), 4.52 (dd, J=5.2, 4.0 Hz, 1H, H3′), 4.34-4.36 (m, 1H, H4′), 4.20-4.08 (m, 2H, H5′, H5″), 3.98-3.88 (m, 2H, CH2—N3), 3.46-3.36 (m, 2H, CH2—O); 31P NMR (202 MHz, Deuterium Oxide) δ 0.94-1.05 (m, 1P, Pα); HRMS (−) ESI m/z found: 431.06262, calc. for: C12H16N8O8P−431.0834196(2).
β-O-(2-Azidoethyl) Guanosine Diphosphate Ammonium Salt (GppOC2H4N3)
DMF (3.7 mL) and MgCl2 (74.2 mg, 0.78 mmol, 4 equiv.) were added to a flask with dry azidoethyl phosphate cyclohexylammonium salt (ca. 0.610 mmol, 3 equiv.) and the mixture was stirred at room temperature until complete dilution of the phosphate subunit. Then, guanosine 5′-monophosphate imidazolide (106 mg, 2353 mOD, 0.195 mmol, 1 equiv.) along with second portion of MgCl2 (74.2 mg, 0.78 mmol, 4 equiv.) were added. The mixture was stirred at room temperature for 24 h. The reaction was then stopped by diluting with ten volumes of water and subjected to ion-exchange purification which afforded 2047 mOD, (0.170 mmol, 87%) of GppOC2H4N3 triethylammonium salt. Additional HPLC purification of a fraction of obtained product gave GppOC2H4N3 as ammonium salt.
1H NMR (500 MHz, Deuterium Oxide) δ 8.35 (s, 1H, H8), 5.97 (d, J=5.5 Hz, 1H, H1′), 4.78 (dd, J=5.1, 5.5 Hz, 1H, H2′), 4.53 (dd, J=5.1, 3.9 Hz, 1H, H3′), 4.37 (dt, J=3.9, 2.3 Hz, 1H, H4′), 4.30-4.18 (m, 2H, H5′ and H5″), 4.06-4.09 (m, 2H, CH2linker CH2-O), 3.48 (t, J=5.0 Hz, 2H, CH2linker CH2-N3); 31P NMR (202 MHz, Deuterium Oxide) δ −10.57-−10.30 (m, 2P, overlapped Pα and Pβ); HRMS (−) ESI m/z found: 511.0503, calc. for: C12H17N8O11P2− 511.0498.
1.9. Synthesis of Dinucleotide Cap Analogues
General Procedure G (GP G): Synthesis of Dinucleotide Cap Analogues Containing Triazole Located Between P-Subunits (Phosphoramidate Analogues)
Aqueous solutions of an alkyne-containing nucleotide (1 equiv., 0.2-1.0 M) and an azide-containing nucleotide (1 equiv., 0.2-1.0 M) were mixed together followed by addition of H2O (to the concentration of each analogue ca. 50-150 mM) and aqueous solutions of CuSO4.5H2O (0.2 equiv., 0.5-6.0 M) and sodium ascorbate (0.4 equiv., 1-12 M). The reaction was stirred at room temperature for several hours and monitored by RP HPLC. Additional portions of CuSO4 or sodium ascorbate solutions were added upon slow kinetics. Final concentrations of reagents are given in the detailed procedures below. When completed, the reaction was quenched by 5-fold dilution with water and addition of Na2EDTA (ten equivalents of added CuSO4) directly followed by semi-preparative RP HPLC purification.
General Procedure G (GP H): Synthesis of Dinucleotide Cap Analogues Containing Triazole Located Between P-Subunits (Phosphorester Analogues)
Aqueous solutions of an alkyne-containing nucleotide (1 equiv., 0.2-0.5 M) and an azide-containing nucleotide (1 equiv., 0.2-0.5 M) were mixed together followed by addition of H2O and the mixture of H2O:t-BuOH (1:1, v/v) (to the concentration of each analogue ca. 26-53 mM, final H2O:t-BuOH (2-5:1, v/v)) and aqueous solutions of CuSO4.5H2O (0.4 equiv., 0.6-0.65 M) and sodium ascorbate (0.8 equiv., 1.2-1.3 M). The reaction was stirred at room temperature for 0.5-1 h and monitored by RP HPLC. Final concentrations of reagents are given in the detailed procedures below. When completed, the reaction was quenched by 5-fold dilution with water and addition of Na2EDTA (ten equivalents of added CuSO4) directly followed by semi-preparative RP HPLC purification.
m7GpNHC2H4-Triazole-CH2ppG
Obtained according to GP G from GppC3H3 (848 mOD, 0.070 mmol, 150 mM) and m7GpNHC2H4N3 (800 mOD, 0.070 mmol, 150 mM) while stirring with CuSO4 (3.5 mg, 0.014 mmol, 30 mM) and sodium ascorbate (5.5 mg, 0.028 mmol, 60 mM) in 0.70 mL of H2O for 1 h. After quenching the reaction with Na2EDTA (52.2 mg, 0.14 mmol), the product was subjected to RP HPLC purification which afforded m7GpNHC2H4-triazole-CH2ppG as ammonium salt.
1H NMR (400 MHz, D2O, 25° C.) δH: 8.03 (1H, s, H8 G), 7.84 (1H, s, J=2.0, Htriazole), 5.98 (1H, d, J1′-2′=3.9, H1′ m7G), 5.88 (1H, d, J1′-2′=5.9, H1′ G), 4.77 (1H, dd, J1′-2′=5.9, J2′-3′=5.1, H2′ G), 4.69 (1H, dd, J1′-2′=3.9, J2′-3′=5.1, H2′ m7G), 4.50 (1H, dd, J2′-3′=5.1, J3′-4′=3.9, H3′ G), 4.42 (1H, dd, J2′-3′=5.1, J3′-4′=5.5, H3′ m7G), 4.37 (2H, br t, JCH2(triazole)m7G-CH2(NH)=6.1, HCH2(triazole)m7G), 4.31-4.34 (2H, m, overlapped H4′ G and m7G), 4.14-4.21 (2H, m, H5′ and H5″ G), 4.00 (1H, ddd, J5′-5″=11.7, J=4.7, 2.7, H5′ m7G), 3.90 (1H, ddd, J5′-5″=11.7, J=4.9, 3.3, H5″ m7G), 3.23-3.28 (2H, m, HCH2(NH)), 3.16 (2H, d, JPβ-CH2(P)=20.2, HCH2(P)); 31P NMR (162 MHz, D2O, 25° C.) δP: 11.70 (1P, dt, JPβ-CH2(P)=20.2, JPα-Pβ26.4, Pβ), 9.01-9.14 (1P, m, Pδ), −10.40 (1P, br d, JPα-Pβ=26.4, Pα); HRMS (−) ESI m/z found: 909.1618, calc. for C26H36N14O17P3−: 909.1596; hydrolysis in D2O: 11%.
m′GpNHC2H4-Triazole-CH2pppG
Obtained according to GP G from GpppC3H3 (742 mOD, 0.061 mmol, 150 mM) and m7GpNHC2H4N3 (700 mOD, 0.061 mmol, 150 mM) while stirring with CuSO4 (3.0 mg, 0.012 mmol, 30 mM) and sodium ascorbate (4.8 mg, 0.024 mmol, 60 mM) in 0.409 mL of H2O for 1 h. After quenching the reaction with Na2EDTA (44.7 mg, 0.12 mmol), the product was subjected to RP HPLC purification which afforded m7GpNHC2H4-triazole-CH2pppG as ammonium salt.
1H NMR (400 MHz, D2O, 25° C.) δH: 8.06 (1H, s, H8 G), 7.88 (1H, d, J=2.0, Htriazole), 5.98 (1H, d, J1′-2′=3.9, H1′ m7G), 5.86 (1H, d, J1′-2′=6.3, H1′ G), 4.79 (1H, dd, J1′-2′=6.3, J2′-3=5.1, H2′ G), 4.74 (1H, dd, J1′-2′=3.9, J2′-3′=5.1, H2′ m7G), 4.54 (1H, dd, J2′-3′=5.1, J3′-4′=3.5, H3′ G), 4.37 (1H, dd, J2′-3=5.1, J2′-3=5.1, H3′ m7G), 4.37 (2H, br t, JCH2(triazole)m7G-CH2(NH)=6.6, HCH2(triazole)m7G), 4.32-4.35 (2H, overlapped H4′ G and H4′ m7G and H5′ G), 4.28 (1H, ddd, J5′-5″=11.7, J=5.3, 3.3, H5′ m7G), 4.23 (1H, ddd, J5′-5″=11.7, J=5.9, 3.9, H5″ m7G), 4.06 (3H, s, m7), 4.02 (1H, ddd, J5′-5″=11.7, J=4.7, 2.7, H5′ G), 3.86 (1H, ddd, J5′-5″=11.7, J=5.1, 3.5, H5′ G), 3.21-3.26 (2H, m, HCH2(NH)), 3.22 (2H, d, JCH2(P)—Pγ=20.4, HCH2(P)); 31P NMR (162 MHz, D2O, 25° C.) δP: 14.20 (1P, dt, JPβ-Pγ=24.9, JPγ-CH2(P)=20.4, Pγ), 11.20-11.32 (1P, m, Pε), −8.35 (1P, dt, JPα-Pβ=19.1 JPα-5′/5″=4.4, Pα), 20.05 (1P, JPα-Pβ=19.1, JPβ-Pγ=24.9, Pβ); HRMS (−) ESI m/z found: 989.1276, calc. for C26H37N14O20P4−: 989.1259; hydrolysis in D2O: 7%.
m7GppCH2-Triazole-C2H4NHpG
Obtained according to GP G from m7GppC3H3 (1132 mOD, 0.099 mmol, 150 mM) and GpNHC2H4N3 (1200 mOD, 0.099 mmol, 150 mM) while stirring with CuSO4 (4.9 mg, 0.020 mmol, 30 mM) and sodium ascorbate (7.9 mg, 0.040 mmol, 60 mM) in 0.662 mL of H2O for 2 h. After quenching the reaction with Na2EDTA (74.5 mg, 0.20 mmol), the product was subjected to RP HPLC purification which afforded m7GppCH2-triazole-C2H4NHpG as ammonium salt.
1H NMR (400 MHz, D2O, 25° C.) δH: 8.01 (1H, s, H8 G), 7.82 (1H, d, J=2.0, Htriazole), 6.02 (1H, d, J1′-2′=3.5, H1′ m7G), 5.86 (1H, d, J1′-2′=5.5, H1′ G), 4.83 (1H, dd, J1′-2′=5.5, J2′-3′=5.5, H2′G), 4.68 (1H, dd, J1′-2′=3.5, J2′-3′=4.7, H2′ m7G), 4.46 (2H, overlapped H3′ G and m7G), 4.35-4.37 (1H, m, H4′ G or m7G), 4.28-4.31 (3H, overlapped H4′ G or m7G, HCH2(triazole)G′), 4.24 (1H, ddd, J5′-5″=11.7, J=4.3, 2.4, H5′ G or m7G), 4.16 (1H, ddd, J5′-5″=11.7, J=5.5, 2.4, H5″ G or m7G), 4.08 (3H, s, m7), 3.96 (1H, ddd, J5′-5″=11.7, J=4.7, 3.1, H5″ G or m7G), 3.88-3.93 (1H, m, H5″ G or m7G), 3.22 (2H, d, JCH2(P)—Pγ=20.5, HCH2(P)), 3.13-3.20 (2H, m, HCH2(NH)); 31P NMR (162 MHz, D2O, 25° C.) δP: 11.95 (1P, dt, JPγ-CH2(P)=20.5, JPγ-Pδ=26.4, Pγ), 9.05-9.18 (1P, m, Pα), −10.34 (1P, br d, JPα-Pβ=26.4, Pδ); HRMS (−) ESI m/z found: 909.1603, calc. for C26H36N14O17P3−: 909.1596.
m7GpppCH2-Triazole-C2H4NHpG
Obtained according to GP G from m7GpppC3H3 (742 mOD, 0.061 mmol, 100 mM) and GpNHC2H4N3 (700 mOD, 0.061 mmol, 100 mM) while stirring with CuSO4 (6.0 mg, 0.024 mmol, 40 mM) and sodium ascorbate (9.6 mg, 0.048 mmol, 80 mM) in 0.614 mL of H2O for 24 h. After quenching the reaction with Na2EDTA (89.4 mg, 0.24 mmol), the product was subjected to RP HPLC purification which afforded m7GpppCH2-triazole-C2H4NHpG as ammonium salt.
1H NMR (400 MHz, D2O, 25° C.) δH: 8.00 (1H, s, H8 G), 7.84 (1H, d, JCH2(P)—H(triazole)=2.2, Htriazole), 6.00 (1H, d, J1′-2′=3.5, H1′ m7G), 5.86 (1H, d, J1′-2′=5.5, H1′ G), 4.89 (1H, dd, J1′-2′=5.5, J2′-3=5.1, H2′ G), 4.69 (1H, dd, J1′-2′=3.5, J2′-3′=5.1, H2′ m7G), 4.56 (1H, dd, J2′-3′=5.1, J3′-4′=5.5, H3′ m7G), 4.47 (1H, dd, J2′-3=5.1, J2′-3=4.3, H3′ G), 4.36-4.41 (2H, overlapped H4′ and H5′ m7G), 4.23-4.30 (4H, overlapped H5″ m7G, H4′G, HCH2(triazole)G), 4.08 (3H, s, m7), 3.98 (1H, ddd, J5′-5″=11.7, J=4.3, 2.9, H5′G), 3.89-3.95 (1H, m, H5″ G), 3.26 (2H, dd, JCH2-Pγ=20.5, JCH2(P)—H(triazole)=2.2, HCH2(P)), 3.07-3.18 (2H, m, HCH2(NH)); 31P NMR (162 MHz, D2O, 25° C.) δP: 14.11 (1H, dt, JPγ-Pδ=24.9, JCH2(P)—Pγ=20.5, Pγ), 11.18-11.37 (1P, m, Pα), −8.40 (1P, br d, JPε-Pδ=19.1, Pε), −19.96 (1P, dd, JPε-Pδ=19.1, JPγ-Pδ=24.9, Pδ); HRMS (−) ESI m/z found: 494.0598, calc. for C26H36N14O20P42−: 494.0590; hydrolysis in D2O: 9%.
m7GpNHC2H4-Triazole-ppG
Obtained according to GP G from GpppC3H3 (700 mOD, 0.061 mmol, 100 mM) and m7GpNHC2H4N3 (742 mOD, 0.061 mmol, 100 mM) while stirring with CuSO4 (6.0 mg, 0.024 mmol, 40 mM) and sodium ascorbate (9.6 mg, 0.048 mmol, 80 mM) in 0.614 mL of H2O for 1 h. After quenching the reaction with Na2EDTA (89.4 mg, 0.24 mmol), the product was subjected to RP HPLC purification which afforded m7GpNHC2H4-triazole-ppG as ammonium salt.
1H NMR (400 MHz, D2O, 25° C.) δH: 8.25 (1H, s, H8 G or Htriazole), 7.94 (1H, s, H8 G or Htriazole), 5.98 (1H, d, J1′-2′=3.9, H1′ m7G), 5.83 (1H, d, J1′-2′=5.9, H1′ G), 4.66 (1H, dd, J1′-2′=5.9, J2′-3=5.1, H2′ G), 4.62 (1H, dd, J1′-2′=3.9, J2′-3′=5.1, H2′ m7G), 4.42-4.46 (3H, overlapped HCH2(triazole)m7G′ and H3′G), 4.37 (1H, dd, J2′-3′=5.1, J3′-4′=5.1, H3′ m7G), 4.29-4.32 (1H, m, H4′ m7G), 4.25-4.28 (1H, m, H4′ G), 4.13-4.15 (2H, m, H5′ and H5″ G), 4.06 (3H, s, m7), 3.92 (1H, ddd, J5′-5″=11.7, J=4.7, 2.7, H5′ m7G), 3.82 (1H, ddd, J5′-5″=11.7, J=5.1, 3.1, H5′ m7G), 3.25-3.31 (2H, m, HCH2(NH)); 31P NMR (162 MHz, D2O, 25° C.) δP: 8.92-9.04 (1P, m, Pδ), −6.87 (1P, d, JPα-Pβ=22.7, Pβ), −10.80 (1P, dt, JPα-Pβ=22.7, JPα-5′/5′″=6.6, Pα); HRMS (−) ESI m/z found: 895.1456, calc. for C25H34N14O17P3−: 895.1439; hydrolysis in D2O: 14%.
m7GpNHC2H4-Triazole-pppG
Obtained according to GP G from GpppC2H (700 mOD, 0.061 mmol, 100 mM) and m7GpNHC2H4N3 (742 mOD, 0.061 mmol, 100 mM) while stirring with CuSO4 (6.0 mg, 0.024 mmol, 40 mM) and sodium ascorbate (9.6 mg, 0.048 mmol, 80 mM) in 0.614 mL of H2O for 2.5 h. After quenching the reaction with Na2EDTA (89.4 mg, 0.24 mmol), the product was subjected to RP HPLC purification which afforded m7GpNHC2H4-triazole-pppG as ammonium salt.
1H NMR (400 MHz, D2O, 25° C.) δH: 8.30 (1H, s, H8 G or Htriazole), 7.03 (1H, s, H8 G or Htriazole), 5.98 (1H, d, J1′-2′=3.7, H1′ m7G), 5.85 (1H, d, J1′-2′=6.3, H1′ G), 4.73 (1H, dd, J1′-2′=6.3, J2′-3=5.1, H2′ G), 4.66 (1H, dd, J1′-2′=3.7, J2′-3′=4.7, H2′ m7G), 4.48 (1H, dd, J2′-3′=5.1, J3′-4′=3.5, H3′ G), 4.45 (2H, br t, JCH2(triazole)m7G-CH2(NH)=5.9, HCH2(triazole)m7G), 4.38 (1H, dd, J2′-3′=4.7, J3′-4′=5.9, H3′ m7G), 4.31-4.34 (1H, m, H4′ m7G), 4.27-4.30 (1H, m, H4′ G), 4.14-4.16 (2H, m, H5′ and H5″ G), 4.06 (3H, s, m7), 3.96 (1H, ddd, J5′-5″=11.7, J=4.7, 2.7, H5′ m7G), 3.84 (1H, ddd, J5′-5″=11.7, J=5.1, 3.5, H5′ m7G), 3.29 (1H, dt, JCH2(triazole)-CH2(NH)=5.9, JCH2(NH)—Pε=10.6, HCH2(NH)′ and HCH2(NH)″); 31P NMR (162 MHz, D2O, 25° C.) δP: 8.94-9.12 (1P, m, Pε), −6.56 (1P, d, JPβ-Pγ=22.0, Pγ), −10.61 (1P, dt, JPα-Pβ=19.1, JPα-5′/5″=5.1, Pα), −22.49 (1p, dd, JPα-Pβ=22.7, JPα-Pβ=19.1, Pβ); HRMS (−) ESI m/z found: 975.1124, calc. for C25H35N14O20P4−: 975.1103; hydrolysis in D2O: 9%.
m7Gpp-Triazole-C2H4NHpG
Obtained according to GP G from m7GppC2H (742 mOD, 0.061 mmol, 100 mM) and GpNHC2H4N3 (700 mOD, 0.061 mmol, 100 mM) while stirring with CuSO4 (6.0 mg, 0.024 mmol, 40 mM) and sodium ascorbate (9.6 mg, 0.048 mmol, 80 mM) in 0.614 mL of H2O for 2 h. After quenching the reaction with Na2EDTA (89.4 mg, 0.24 mmol), the product was subjected to RP HPLC purification which afforded m7Gpp-triazole-C2H4NHpG as ammonium salt.
1H NMR (400 MHz, D2O, 25° C.) δH: 8.24 (1H, s, H8 G or Htriazole), 8.03 (1H, s, H8 G or Htriazole), 5.99 (1H, d, J1′-2′=3.3, H1′ m7G), 5.84 (1H, d, J1′-2′=5.9, H1′ G), 4.75 (1H, dd, J1′-2′=5.9, J2′-3=5.1, H2′ G), 4.64 (1H, dd, J1′-2′=3.3, J2′-3′=4.7, H2′ m7G), 4.41-4.45 (2H, overlapped with H3′ G and H3′ m7G), 4.39 (2H, br t, JCH2(triazole)G-CH2(NH)=6.3, HCH2(triazole)G), 4.34-4.36 (1H, m, H4′ m7G), 4.24-4.29 (2H, m, overlapped H5′ m7G and H4′ G), 4.18 (1H, ddd, J5′-5″=11.9, J=5.5, 2.3, H5″ m7G), 4.04 (3H, s, m7), 3.90 (1H, ddd, J=J5′-5″=11.7, J=4.5, 2.9, H5′ G), 3.77-3.83 (1H, m, H5″ G), 3.17-3.28 (2H, m, HCH2(NH)); 31P NMR (162 MHz, D2O, 25° C.) δP: 8.93-9.1 (1P, m, Pα), −6.62 (1P, d, JPγ-Pδ23.5, Pγ), −10.75 (1P, br d, JPγ-Pδ=23.5, Pδ); HRMS (−) ESI m/z found: 895.1454, calc. for C25H34N14O17P3−: 895.1439.
m7Gppp-Triazole-C2H4NHpG
Obtained according to GP G from m7GpppC2H (742 mOD, 0.061 mmol, 50 mM) and GpNHC2H4N3 (700 mOD, 0.061 mmol, 50 mM) while stirring with CuSO4 (6.0 mg, 0.024 mmol, 20 mM) and sodium ascorbate (9.6 mg, 0.048 mmol, 40 mM) in 1.228 mL of H2O for 1 h. After quenching the reaction with Na2EDTA (89.4 mg, 0.24 mmol), the product was subjected to RP HPLC purification which afforded m7Gppp-triazole-C2H4NHpG as ammonium salt.
1H NMR (400 MHz, D2O, 25° C.) δH: 8.23 (1H, s, H8 G or Htriazole), 8.02 (1H, s, H8 G or Htriazole), 6.00 (1H, d, J1′-2′=3.5, H1′ m7G), 5.86 (1H, d, J1′-2′=5.5, H1′ G), 4.84 (1H, dd, J1′-2′=5.5, J2′-3=5.1, H2′ G), 4.66 (1H, dd, J1′-2′=3.5, J2′-3′=4.7, H2′ m7G), 4.51 (1H, dd, J2′-3′=4.7, J3′-4′=5.5, H3′ m7G), 4.44 (1H, dd, J2′-3=5.1, J2′-3=3.9, H3′ G), 4.27-4.37 (5H, overlapped H4′ G and H4′ m7G and H5′ G or m7G, HCH2(triazole)), 4.20 (1H, ddd, J5′-5″=11.7, J=5.5, 2.4, H5″ G or m7G), 4.07 (3H, s, m7), 3.94 (1H, ddd, J5′-5″=11.5, J=4.3, 3.1, H5′ m7G or G), 3.84-3.89 (1H, m, H5′ m7G or G), 3.13-3.24 (2H, m, HCH2(NH)); 31P NMR (162 MHz, D2O, 25° C.) δP: 11.0.8-11.21 (1P, m, Pα), −4.38 (1P, d, JPβ-Pγ=22.0, Pγ), −8.41 (1P, br d, JPα-Pβ=19.1, Pε), −20.26 (1p, dd, JPα-Pβ=22.0, JPα-Pβ=19.1, Pγ); HRMS (−) ESI m/z found: 975.1122, calc. for C25H35N14O20P4−: 975.1103; hydrolysis in D2O: 13%.
m27,2′-OGppp-Triazole-C2H4NHpG
Obtained according to GP G from m27,2′-OGpppC2H (650 mOD, 0.057 mmol, 100 mM) and GpNHC2H4N3 (689 mOD, 0.061 mmol, 50 mM) while stirring with CuSO4.5H2O (2.7 mg, 0.011 mmol, 20 mM) and sodium ascorbate (4.4 mg, 0.022 mmol, 40 mM) in 0.570 mL of H2O:t-BuOH (2:1, v/v) for 2 h. After quenching the reaction with Na2EDTA (89.4 mg, 0.24 mmol), the product was subjected to RP HPLC purification which afforded m27,2′-OGppp-triazole-C2H4NHpG as ammonium salt.
1H NMR (400 MHz, D2O, 25° C.) δH: 9.14 (1H, q, JH8-m7=0.8, H8 m7G), 8.24 (1H, s, H8 G or Htriazole), 8.02 (1H, s, H8 G or Htriazole), 6.06 (1H, d, J1′-2′=2.7, H1′ m7G), 5.84 (1H, d, J1′-2′=5.5, H1′ G), 4.80 (1H, overlapped with HDO, H2′ G), 4.58 (1H, dd, J=6.2, 4.7, H3′ m7G), 4.42 (1H, dd, J=5.1, 3.9, H3′ G), 4.27-4.36 (6H, overlapped H2′m7G, H4′ G and m7G, H5′ G or m7G, HCH2(triazole)), 4.18 (1H, ddd, J5′-5″=12.3, J=5.3, 2.7, H5″ G or m7G), 4.06 (3H, d, JH8-m7=0.8, m7), 3.92 (1H, ddd, J5′-5″=11.7, J=4.3, 3.1, H5′ G or m7G), 3.84 (1H, ddd, J5′-5″=11.7, J=5.1, 4.7), 3.59 (3H, s, m2′O), 3.12-3.26 (2H, m, HCH2(NH)); 31P NMR (162 MHz, D2O, 25° C.) δP: 8.95-9.15 (1P, m, Pα), −6.57 (1P, d, JPγ-Pδ=21.3, Pγ), −10.64 (1P, ddd, JPε-Pδ=19.1, JPε-5′=4.4, JPε-5″=2.9, Pε), −22.42 (1P, dd, JPγ-Pδ=21.3, JPε-Pδ=19.1, Pδ); HRMS (−) ESI m/z found: 989.1272, calc. for C26H37N14O20P4−: 989.1259; hydrolysis in D2O: 8%.
m7GppNHC2H4-Triazole-C2H4ppG
Obtained according to GP G from GppC4H5 (580 mOD, 0.048 mmol, 100 mM) and m7GppNHC2H4N3 (437 mOD, 0.038 mmol, 80 mM) while stirring with CuSO4 (4.8 mg, 0.019 mmol, 40 M) and sodium ascorbate (7.5 mg, 0.038 mmol, 80 mM) in 0.485 mL of H2O for 0.5 h. After quenching the reaction with Na2EDTA (0.7 mg, 0.19 mmol), the product was subjected to RP HPLC purification which afforded m7GppNHC2H4-triazole-C2H4ppG as ammonium salt.
1H NMR (400 MHz, D2O, 25° C.) δH: 9.16 (1H, s, H8 m7G), 8.06 (1H, s, H8 G or Htriazole), 7.71 (1H, s, H8 G or Htriazole), 6.00 (1H, d, J1′-2′=2.7, H1′ G or m7G), 5.88 (1H, d, J1′-2′=5.5, H1′ G or m7G), 4.80 (1H, overlapped with HDO, H2′ G or m7G), 4.69 (2H, dd, J1′-2′=2.7, J3′-4′=5.1, H2′ G or m7G), 4.49-4.54 (2H, overlapped H3′ G and m7G), 4.35-4.39 (4H, overlapped H4′ G and m7G, HCH2(triazole)m7G), 4.18-4.33 (4H, overlapped H5′ and H5″G and m7G), 4.06 (3H, s, m7), 3.30 (2H, dt, JCH2(NH)—Pδ=11.9, JCH2(NH)—CH2(triazole)m7G=6.5, HCH2(NH)), 2.78 (2H, m, HCH2(triazole)G or HCH2(P)), 1.99 (2H, m, HCH2(triazole)G or HCH2(P)); 31P NMR (162 MHz, D2O, 25° C.) δP: 17.61-18.01 (1P, m, Pβ), −1.54 (1P, dt, JPδ-Pε=21.3, JPδ-CH2(NH)=11.9, Pδ), −10.27 (1P, br d, JPδ-Pε=21.3, Pε), −10.52 (1P, br d, JPα-Pβ=27.9, Pα); HRMS (−) ESI m/z found: 1003.1435, calc. for C27H39N14O20P4−: 1003.1421; hydrolysis in D2O: 11%.
m7GppC2H4-Triazole-C2H4NHppG
Obtained according to GP G from m7GppC4H5 (375 mOD, 0.033 mmol, 100 mM) and GppNHC4H5N3 (397 mOD, 0.033 mmol, 100 mM) while stirring with CuSO4 (1.6 mg, 0.0066 mmol, 20 mM) and sodium ascorbate (2.6 mg, 0.013 mmol, 40 mM) in 0.328 mL of H2O for 1 h. After quenching the reaction with Na2EDTA (24.6 mg, 0.066 mmol), the product was subjected to RP HPLC purification which afforded m7GppC2H4-triazole-C2H4NHppG as ammonium salt.
1H NMR (400 MHz, D2O, 25° C.) δH: 9.18 (1H, s, H8 m7G), 8.12 (1H, s, H8 G or Htriazole), 7.69 (1H, s, H8 G or Htriazole), 6.02 (1H, d, J1′-2′=3.5, H1′ G or m7G), 5.88 (1H, d, J1′-2′=5.5, H1′ G or m7G), 4.72-4.76 (2H, overlapped H2′ G and m7G), 4.50-4.54 (2H, overlapped H3′ G and m7G), 4.40-4.43 (1H, m, H4 G or m7G), 4.33-4.39 (2H, overlapped H4′ G or m7G and H5′ G or m7G), 4.28 (2H, br t, JCH2(triazole)G-CH2(NH)=6.6, HCH2(triazole)G), 4.17-4.29 (3H, overlapped H5″ G and m7G and H5′ G or m7G), 4.06 (3H, s, m7), 3.20-3.28 (2H, m, HCH2(NH)), 2.79-2.85 (2H, m, HCH2(triazole)m7G) or HCH2(P)), 1.99-2.08 (2H, m, HCH2(triazole)m7G) or HCH2(P)); 31P NMR (162 MHz, D2O, 25° C.) δP: 17.61-18.10 (1P, m, Pδ), −1.64 (1P, dt, JPα-Pβ=22.0, JPβ-CH2(NH)=12.5, Pβ), −10.22 (1P, br d, JPα-Pβ=22.0, Pα), −10.50 (1P, br d, JPδ-Pε=24.9, Pε); HRMS (−) ESI m/z found: 1003.1444, calc. for C27H39N14O20P4−: 1003.1421; hydrolysis in D2O: 10%.
m27,2′-OGppp-Triazole-C2H4NHppG (m27,2′-OGppptC2H4NHppG)
Obtained according to GP H from m27,2′-OGpppC2H (377 mOD, 0.033 mmol, 50 mM) and GppNHC2H4N3 (400 mOD, 0.033 mmol, 50 mM) while stirring with CuSO4 (3.3 mg, 0.013 mmol, 20 mM) and sodium ascorbate (5.2 mg, 0.026 mmol, 40 mM) in 662 mL of H2O:t-BuOH (2:1, v/v) for 0.5 h. After quenching the reaction with Na2EDTA (48.4 mg, 0.13 mmol), the product was subjected to RP HPLC purification which afforded m7Gppp-triazole-C2H4NHppG as ammonium salt.
1H NMR (500 MHz, Deuterium Oxide) δ 9.13 (s, 1H, H8 m7G), 8.24 (s, 1H, H8 G or Htriazole), 8.06 (s, 1H, H8 G or Htriazole), 6.08 (d, J=3.1 Hz, 1H, H1′ m7G), 5.87 (d, J=5.8 Hz, 1H, H1′ G), 4.82 (overlapped with HDO, 1H, H2′ G), 4.59 (dd, J=6.1, 4.9 Hz, 1H, H3′ m7G), 4.52 (dd, J=5.3, 3.7 Hz, 1H, H3′ G), 4.42 (t, J=6.4 Hz, 2H, HCH2-triazole), 4.35-4.26 (m, 4H, overlapped H2′ m7G, H4′ G and m7G, H5′ G or m7G), 4.25-4.13 (m, 3H, overlapped H5′ G or m7G, H5″ G and m7G), 4.07 (s, 3H, m7), 3.59 (s, 3H, m2′O), 3.32 (dt, J=12.6, 6.4 Hz, 2H, HCH2-NH); 31P NMR (202 MHz, Deuterium Oxide) δ −1.36-−1.72 (m, 1P, Pβ), −6.34 (d, J=21.8 Hz, 1P, Pδ), −10.04-−10.29 (m, 1P, Pα), −10.49-−10.65 (m, 1P, Pζ), −22.34 (dd, J=21.8, 19.7 Hz, 1P, Pε); HRMS (−) ESI m/z found: 1069.0946, calc. for: C26H38N14O23P5− 1069.0928.
m27,2′-OGppp-Triazole-C2H4OppG (m27,2′-OGppptC2H4OppG)
Obtained according to GP H from m27,2′-OGpppC2H (330 mOD, 0.029 mmol, 48 mM) and GppOC2H4N3 (350 mOD, 0.029 mmol, 48 mM) while stirring with CuSO4 (2.9 mg, 0.012 mmol, 19 mM) and sodium ascorbate (4.6 mg, 0.023 mmol, 38 mM) in 0.600 mL of H2O:t-BuOH (5:1, v/v) for 1 h. After quenching the reaction with Na2EDTA (44.7 mg, 0.12 mmol), the product was subjected to RP HPLC purification which afforded m7Gppp-triazole-C2H4OppG as ammonium salt.
1H NMR (500 MHz, Deuterium Oxide) δ 9.15 (s, 1H, H8 G or m7G or Htriazole), 8.38 (s, 1H, H8 G or m7G or Htriazole), 8.30 (s, 1H, H8 G or m7G or Htriazole), 6.09 (d, J=3.1 Hz, 1H, H1′ m7G), 5.93 (d, J=5.3 Hz, 1H, H1′ G), 4.77 (t, 1H, overlapped with HDO, H2′ G), 4.66 (t, J=5.4 Hz, 2H, CH2linker CH2-N), 4.58 (dd, J=6.0, 4.9 Hz, 1H, H3′ m7G), 4.48 (dd, J=5.1, 4.0 Hz, 1H, H3′ G), 4.39-4.26 (m, 6H, overlapped H2′ m 7G, CH2linker CH2-O, H4′G, H4′ m7G, H5′ G or m7G), 4.11-4.23 (m, 3H, H4′ m7G, H5′ G or m7G, H5′ and H5″ G or m7G), 4.08 (s, 3H, m7), 3.59 (s, 3H, m2′-O); 31P NMR (202 MHz, Deuterium Oxide) δ −6.58 (d, J=21.6 Hz, 1P), −10.08-−10.87 (m, 3P, overlapped), −22.34 (t, J=20.6 Hz, 1P, Pδ); HRMS (−) ESI m/z found: 1070.0792, calc. for: C26H37N13O24P5− 1070.0768.
m27,2′-OGppp-Triazole-C2H4OpG (m27,2′-OGppptC2H4OpG)
Obtained according to GP H from m27,2′-OGpppC2H (330 mOD, 0.029 mmol, 25 mM) and GpOC2H4N3 (350 mOD, 0.029 mmol, 25 mM) while stirring with CuSO4 (2.9 mg, 0.012 mmol, 10 mM) and sodium ascorbate (4.6 mg, 0.023 mmol, 20 mM) in 1.150 mL of H2O:t-BuOH (3:1, v/v) for 0.5 h. After quenching the reaction with Na2EDTA (44.7 mg, 0.12 mmol), the product was subjected to RP HPLC purification which afforded m7Gppp-triazole-C2H4OpG as ammonium salt.
1H NMR (500 MHz, Deuterium Oxide) δ 9.14 (s, 1H, H8 G or m7G Htriazole), 8.31 (s, 1H, H8 G or m7G or Htriazole), 8.05 (s, 1H, H8 G or m7G Htriazole), 6.06 (d, J=2.9 Hz, 1H, H1′ m7G), 5.83 (d, J=5.8 Hz, 1H, H1′ G), 4.70 (dd, J=5.2, 5.8 Hz, 1H, H2′ G), 4.65 (t, J=5.2 Hz, 2H, CH2 linker CH2-N3), 4.57 (dd, J=6.3, 4.9 Hz, 1H, H3′ m7G), 4.27-4.34 (m, 4H, overlapped H2′ m7G and H3′ G, H4′ G or H5′ or H5″ m7G), 4.27-4.22 (m, 1H, H4′ G), 4.16-4.21 (m, 3H, overlapped CH2 linker CH2-O and H4′ G or H5′ or H5″ m7G), 4.06 (s, 3H, m7), 3.87 (ddd, J=11.6, 4.6, 2.9 Hz, 1H), 3.81 (ddd, J=11.6, 5.2, 4.0 Hz, 1H), 3.60 (s, 3H, m2′-O); 31P NMR (202 MHz, Deuterium Oxide) δ 0.65-0.67 (m, 1P, Pα), −6.73 (d, J=22.2 Hz, 1P, Pγ), −10.49-−10.69 (m, 1P, Pε), −22.36 (dd, J=22.2, 18.7 Hz, 1P, Pδ); HRMS (−) ESI m/z found: 990.1097, calc. for: C26H36N13O21P4− 990.11047.
m27,2′-OGpp-Triazole-C2H4OppG (m27,2′-OGpptC2H4OppG)
Obtained according to GP H from m27,2′-OGppC2H (330 mOD, 0.029 mmol, 48 mM) and GppOC2H4N3 (350 mOD, 0.029 mmol, 48 mM) while stirring with CuSO4 (2.9 mg, 0.012 mmol, 19 mM) and sodium ascorbate (4.6 mg, 0.023 mmol, 38 mM) in 0.600 mL of H2O:t-BuOH (5:1, v/v) for 1 h. After quenching the reaction with Na2EDTA (44.7 mg, 0.12 mmol), the product was subjected to RP HPLC purification which afforded m7Gpp-triazole-C2H4OppG as ammonium salt.
1H NMR (500 MHz, Deuterium Oxide) δ 9.13 (s, 1H, H8 G or m7G or Htriazole), 8.31 (s, 1H, H8 G triazole, or m7G or Htriazole), 8.09 (s, 1H, H8 G or m7G or Htriazole), 6.06 (d, J=3.0 Hz, 1H, H1′ m7G), 5.85 (d, J=6.0 Hz, 1H, H1′ G), 4.75 (dd, J=5.1, 6.0 Hz, 1H, H2′ G), 4.68 (t, J=5.1 Hz, 2H, CH2linker CH2-N), 4.53 (dd, J=6.1, 4.9 Hz, 1H, H3 m7G), 4.47 (dd, J=5.1, 3.4 Hz, 1H, H3′ G), 4.38-4.29 (m, 5H, overlapped overlapped H2′ m7G, CH2linker CH2-O, H4′G, H4′ m7G), 4.26 (ddd, J=11.9, 4.7, 2.6 Hz, 1H, H5′ G or m7G), 4.12-4.19 (m, 2H, overlapped H5′ G or m7G, H5″ G or m7G), 4.05-4.10 (m, 1H, H5″ G or m7G), 4.04 (s, 3H, m7), 3.59 (s, 3H, m2′-O); 31P NMR (202 MHz, Deuterium Oxide) δ −6.52 (d, J=24.3 Hz, 1P), −10.70-−10.37 (m, 3P); HRMS (−) ESI m/z found: 990.1133, calc. for: C26H36N13O21P4− 990.1105.
Association constants for cap analogue-eIF4E complexes were determined using fluorescence quenching titration method as described previously.42 Measurements were performed using a quartz cuvette with optical path length of 4 mm for absorption and 10 mm for emission on LS-50B spectrofluorometer Perkin-Elmer Co. (Waltham, Mass., USA). Titration experiments were carried out at 20° C. in 50 mM Hepes/KOH buffer, pH 7.20 containing 100 mM KCl, 0.5 mM EDTA, and 1 mM DTT. During the experiment 1 μl aliquots of ligand solution was added to the 1400 μl of 0.1 μM protein solution. Protein fluorescence was monitored at 337 or 345 nm (excitation 280 or 295 nm, respectively). For data analysis fluorescence intensity correction was applied for sample dilution and inner filter effect. Association constants were determined by fitting theoretical dependence of fluorescence intensity on total ligand concentration. Each experiment was performed in triplicate, the association constants were calculated as weighted averages.
Table 2. lists the KAS values for complexes of eIF4E and selected phosphotriazole cap analogues compared to reference cap analogues.
Table 3. lists sequences of DNA and RNA of oligonucleotides used in molecular biology experiments.
3.1. Synthesis of Transcripts for Capping Efficiency Determination
Prior to in vitro transcription annealing of a template was performed. DNA1 (SEQ ID NO: 1) and DNA2 (SEQ ID NO: 2) (20 μM each) were incubated in the presence of 4 mM Tris-HCl pH 8.0, 15 mM NaCl and 0.1 mM EDTA at 95° C. for 2 min and then at room temperature for 30 min. After 10-fold dilution the mixture was directly used for in vitro transcription.
In vitro transcription was performed on pre-annealed DNA1 (SEQ ID NO: 1) and DNA2 (SEQ ID NO: 2) (0.5 μM) with SP6 RNA polymerase (New England BioLabs) (1 U/μl) in the presence of 1×RNA Pol Reaction Buffer (New England BioLabs), 5 mM DTT, RiboLock RNase Inhibitor (ThermoFisher Scientific) (2.0 U/μl), 0.5 mM UTP, 0.5 mM ATP, 0.5 mM CTP, 0.125 mM GTP and 1.25 mM of appropriate triazole-modified dinucleotide cap analogue (m27,2′-OGppp-triazole-G, m27,2′-OGppp-triazole-C2H4NHpG, m27,2′-OGppp-triazole-C2H4NHppG, m27,2′-OGppp-triazole-C2H4OppG, m27,2′-OGppp-triazole-C2H4OpG, m27,2′-OGpp-triazole-C2H4OppG) and reference GpppG, m7GpppG and m27,3′-OGpppG.6 The reaction mixture was incubated at 40° C. for 1.5 h followed by addition of TURBO Dnase (Ambion) (0.1 U/μl) and incubation at 37° C. for another 30 min. The reaction was quenched by addition of 2 μl of 0.5 M EDTA pH 8.0 and purified with RNA Clean&Concentrator-5 kit (Zymo Research) to afford capped RNA1 (SEQ ID NO: 4) strands.
To reduce heterogeneity, each capped RNA1 (11.42 ng/μl, ca. 1 μM) was incubated in presence of 50 mM Tris-HCl pH 8.0, 50 mM MgCl2, RiboLock RNase Inhibitor (ThermoFisher Scientific) (2.0 U/μl) and DNA3 (SEQ ID NO: 3) (1 μM) at 37° C. for 1 h to afford RNA2 (SEQ ID NO: 5).44 The reaction was stopped by freezing in liquid nitrogen and directly analyzed by PAGE (
Relative bands intensity was determined using CLIQS v1.0 program.
4.1. Synthesis of Transcripts
In vitro transcription was performed on PCR product coding Firefly luciferase under the control of SP6 promoter (obtained from pGEN-luc (Promega) using primers: DNA4 (SEQ ID NO: 6) and DNA5 (SEQ ID NO:7) (5 ng/μl) with SP6 RNA polymerase (1 U/μl) (New England BioLabs) in the presence of 1×RNA Pol Reaction Buffer (New England BioLabs), 5 mM DTT, RiboLock RNase Inhibitor (ThermoFisher Scientific) (2.0 U/μl), 0.5 mM UTP, 0.5 mM ATP, 0.5 mM CTP, 0.125 mM GTP and 1.25 mM of appropriate triazole-modified dinucleotide cap analogue and reference GpppG, m7GpppG and m27,3′-OGpppG. The reaction mixture was incubated at 40° C. for 1.5 h followed by addition of TURBO Dnase (Ambion) (0.1 U/μl) and incubation at 37° C. for another 30 min. The reaction was quenched by addition of 2 μl of 0.5 M EDTA pH 8.0 and purified with NucleoSpin RNA Clean-up XS kit (Macherey-Nagel) to afford luciferase-coding RNA strands capped with appropriate cap analogue.
4.2. Translation
For each capped luciferase-coding RNA four diluted solutions were prepared—3.0 ng/μl, 1.5 ng/μl, 0.75 ng/μl, 0.375 ng/μl. Translation studies were performed using Rabbit Reticulocyte Lysate System (Promega). 9 μl of a mixture containing Rabbit Reticulocyte Lysate (4 μl), Amino Acid Mixture Minus Leucine (0.05 μl of 1 mM solution), Amino Acid Mixture Minus Methionine (0.05 μl of 1 mM solution), potassium acetate (1.9 μl of 1 M solution), MgCl2 (0.4 μl of 25 mM solution) and 2.1 μl of water was incubated at 30° C. for 1 h after which 1 μl of appropriate luciferase-coding RNA solution was added and incubation of the reaction was continued at 37° C. for another hour. The reaction was stopped by freezing in liquid nitrogen.
Translation efficiency was determined using Luciferase Reporter System (Promega). The samples were defrosted just before the experiment. To every sample 50 μl of Luciferase Assay Reagent was added just before measurement of luminescence on Synergy H1 Microplate Reader (Bio Tek). The measurement were performed for every four samples independently due to low stability of luminescence signal. The results are presented on.
Table 4. lists capping efficiencies for short oligonucleotides terminated with phospotriazole cap analogs and translation efficiencies in rabbit reticulocyte lysates for mRNAs encoding firefly luciferase capped with different phosphotriazole analogs. It also lists corresponding data for unmodified cap analog (m7GpppG), unmodified ARCA (m27,3′-OGpppG), and example cap analogs containing triazole moiety within the nucleoside moiety for comparison (m7GtpppG and m7GtCH2OpppG).
The reaction mixture containing synthesized RNA2 (SEQ ID NO: 5) capped with m27,3′-OGpppG, m27,2′-OGppp-triazole-G and m27,2′-OGppp-triazole-C2H4NHpG (for details of the synthesis see 1.4.1) was precipitated and the pellet was dissolved in water and incubated in the presence of 1×TURBO DNase Buffer (Ambion), RiboLock RNase Inhibitor (ThermoFisher Scientific) (2.0 U/μl) and TURBO Dnase (Ambion) (0.1 U/μl) at 37° C. for 30 min. The reaction was then subjected to phenol-chloroform extraction followed by precipitation. The resulting RNA2 water solution was directly used for Dcp2-catalyzed decapping experiments.
Appropriate RNA2 was incubated in the presence of 50 mM NH4Cl, 5 mM MgCl2, 50 mM Tris-HCl pH 8.0, 0.01% IGEPAL CA-630 (Sigma Aldrich), 2 mM MnCl2, 1 mM DTT and 7 nM hDcp2 at 37° C. 5 μl aliquots of the reaction were collected after 5, 15, 30, 60 min of incubation or just after addition of the enzyme (“0 min” timepoint) and quenched with loading dye (5 M urea, 44% formamide, 20 mM EDTA, 0.03% bromophenol blue, 0.03% xylene cyanol) and directly analyzed by 15% PAGE (
Analogues m27,2′-OGppp-triazole-C2H4NHppG, m27,2′-OGppp-triazole-C2H4OppG, m27,2′-OGppp-triazole-C2H4OpG, m27,2′-OGpp-triazole-C2H4OppG were incubated in sealed vials at 20 μM and at room temperature in four different buffers: 0.1 M formate buffer pH 3.0, 0.1 M acetate buffer pH 5.0, 0.1 M HEPES pH 7.0 and 0.1 M borate buffer pH 9.0. Samples of 50 μl for each condition were taken after 0, 2 and 24 h and analysed by RP HPLC. The starting compound peak area was determined for each time-point and % of remaining cap was calculated in reference to the time-point 0 h.
(The numbers within the application written in upper index indicate one of the below literature document to which they refer)
| Number | Date | Country | Kind |
|---|---|---|---|
| 417980 | Jul 2016 | PL | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/IB2017/054221 | 7/12/2017 | WO | 00 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2018/015845 | 1/25/2018 | WO | A |
| Number | Date | Country |
|---|---|---|
| 2013059475 | Apr 2013 | WO |
| Entry |
|---|
| Walczak et al. (2014) “Synthesis and properties of dinucleotide cap analogs containing a triazole ring within the oligophosphate bridge” Collection Symposium Series, vol. 14, pp. 289-290. |
| Walczak et al. (2017) “A novel route for preparing 5′ cap mimics and capped RNAs: phosphate-modified cap analogues obtained via click chemistry” Chemical Science, vol. 8, No. 1, pp. 260-267. |
| Wanat et al. (2015) “Ethynyl, 2-Propynyl, and 3-Butynyl C-Phosphonate Analogues of Nucleoside Di- and Triphosphates: Synthesis and Reactivity in CuAAC”, Organic Letters, vol. 17, No. 12, pp. 3062-3065. |
| Number | Date | Country | |
|---|---|---|---|
| 20200055891 A1 | Feb 2020 | US |
